Portable SERS-based lateral flow immunoassay strips with self-calibration for detection of a prostate cancer biomarker

Serum prostate-specific antigen (PSA) is thought to be the most vital indicator for early identification, staging and monitoring of prostate cancer (PCa). Although lateral flow immunoassay (LFA) has demonstrated limitless promise for point-of-care testing (POCT) and has drawn increasing interest and attention, there are significant restrictions on the assay ' s sensitivity and quantitative capability. Surface-enhanced Raman spectroscopy-based LFA (SERS-LFA) technique integrates the great sensitivity of SERS with the simplicity, rapidity, and usability of the LFA technique, making it ideal for POCT. In this paper, we propose a sensitive self-calibrating SERS-LFA platform, which uses Au@MBN@Ag@PSA NPs as a SERS immunoprobe for the specific recognition of PSA and loads graphene oxide/gold nanoparticles (GO/Au NPs) on nitrocellulose (NC) membranes as an internal standard (IS) molecule. The SERS-LFA platform's detection accuracy is increased through dynamic calibration of the characteristic signals, which is accomplished by detecting the immunoprobe and IS signals simultaneously and computing their respective signal intensity ratios. The self-calibrated SERS-LFA platform demonstrated a 1.65 -fold improvement in reproducibility over the conventional SERS-LFA, and PSA could only be detected to a limit of 0.08 ng/mL, meaning that it was 3.5-fold lower than the conventional SERS-LFA platform. The spike recovery experiments yielded recoveries of 96.16 similar to 104.53% with RSD values of 9.37%, 8.66%, and 3.49%, respectively, demonstrating that our self-calibrated SERS-LFA platform for PSA quantification has an acceptable level of precision and has great prospect for early screening of PCa and other diseases.